


LABORATORY MEDICINE: Critical to Managing Through the COVID-19 Global Pandemic and Economic Recovery





COVID-19 (SARS-CoV-2) is a respiratory disease associated with endothelialitis and microthrombosis⁽¹⁾ and is the largest global pandemic since the Spanish Flu in 1918.


- Initial cluster of cases of COVID-19 reported in Wuhan, China in January, 2020.⁽²⁾
- First Canadian case of COVID-19 was reported by Health Canada on January 25, 2020.⁽³⁾
- Global COVID-19 pandemic was declared by the World Health Organization on March 11, 2020.⁽²⁾

Millions of people around the world have been infected with COVID-19, resulting in serious illness and death. Individuals with moderate to severe illness requiring hospitalization have severely stressed the healthcare system.

^{**} Numbers as of April 29, 2021
Sources: <https://www.worldometers.info/coronavirus/> and <https://health-infobase.canada.ca/covid-19/epidemiological-summary-covid-19-cases.html>

		
COVID-19 cases	1,202,737 [†]	150,734,026 [*]
COVID-19 related deaths	24,117 [†]	3,170,401 [*]




COVID-19 Timeline






Testing for COVID-19

- Rapid diagnosis of symptomatic patients and identification of asymptomatic infectious individuals could have potentially reduced the scope of the pandemic.
- Initially, no diagnostic tests were available.
- Development of accurate testing methods began in January before the pandemic was declared.
- Highly sensitive tests could have facilitated the earlier detection of influenza and/or COVID-19, permitting appropriate and timely medical management and a reduction in transmission.⁽⁵⁻⁸⁾

A number of Canadian laboratory medicine accomplishments over the year since the pandemic was declared are noteworthy:

- 
 Three types of tests for COVID-19 were developed.
- 
 The first COVID-19 tests were developed in less than one month.
- 
 Over 31,173,221 individual tests have been conducted in Canada.⁽⁹⁾

Three categories of COVID-19 tests have been developed

Test Type Category	What is Tested	Primary Purpose	Sampling Methods	Setting	Scalability*
 Antigen	Viral proteins	<ul style="list-style-type: none"> • Presumptive diagnosis • Screening 	<ul style="list-style-type: none"> • Nasal/nasopharyngeal swabs 	Point of care	+++
				Central or Hospital Laboratory	+++
 PCR or Nucleic Acid	Viral Genetic Material	<ul style="list-style-type: none"> • Diagnosis • Screening 	<ul style="list-style-type: none"> • Nasal/nasopharyngeal swabs • Saliva sample 	Point of care	++
				Central or Hospital Laboratory	+++
 Serological (Antibody)	Antibodies to SARS-CoV-2 (COVID-19 Virus)	<ul style="list-style-type: none"> • Epidemiology 	<ul style="list-style-type: none"> • Blood sample 	Point of care	-/+
				Central or Hospital Laboratory	+++

Note: Point of Care means the technology can be used in decentralized settings (i.e. doctors' offices, pharmacies, clinics, schools, workplaces)

*Scalability refers to the capacity to adapt to changes in demand.

Development of diagnostic tests for COVID-19 delivers on the *Quadruple Aim*



Improve patient outcomes

- Technological advancements in testing will reduce costs and turnaround times for results.
- von Willebrand factor antigen is a predictive factor for in-hospital mortality in patients with COVID-19 and is believed to drive microthrombosis in COVID-19.⁽¹⁾
- Early and rapid diagnosis of this disease will help in early management of patients.⁽¹⁰⁾



Improve health of general population

- The Canadian government identified optimizing diagnostic capacity with lab-based PCR testing and deploying rapid tests for screening to reduce the prevalence of infections and protect Canada's most vulnerable populations.⁽¹¹⁾
- More vigorous testing strategies, including screening and more frequent testing, could enable more rapid identification and isolation of COVID-19 infected individuals, leading to better management and control of the pandemic.⁽¹³⁾



Improve healthcare sustainability

- The Canadian government identified optimizing diagnostic capacity with lab-based PCR testing and deploying rapid tests for screening to limit the impact of the disease on the health care system and the economy.⁽¹¹⁾
- Expanded testing approaches allow proactive response (including asymptomatic individuals) and would lead to more robust and comprehensive solutions to COVID-19 management and control.⁽¹²⁾



Improve care team well-being

- Health care team well-being is linked to patient experiences.⁽⁴⁾
- Having a selection of tests can give clinicians confidence to select the best test for the patient and allow clinicians to efficiently manage the disease.

Laboratory medicine has developed a toolbox of tests and testing strategies to help manage and control the pandemic and drive economic recovery.

References

1. Philippe A, Chocron R, Gendron N et al. Circulating Von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality. *Angiogenesis*. 2021;Jan 15:1-13.
2. World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. Available at: <https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19--11-march-2020>. Accessed March 19, 2021.
3. Bronca T. COVID-19: A Canadian timeline. Available at: <https://www.canadianhealthcare-network.ca/covid-19-a-canadian-timeline>. Accessed March 17, 2021.
4. Government of Canada. Coronavirus disease 2019 (COVID-19): epidemiology update. Available at: <https://health-infobase.canada.ca/covid-19/epidemiological-summary-covid-19-cases.html#a4>. Accessed March 22, 2021.
5. Munoz FM, Campbell JR, Atmar RL et al. Influenza A virus outbreak in a neonatal intensive care unit. *Pediatr Infect Dis J*. 1999;18:811-15.
6. Beekmann SE, Engler HD, Collins AS, Canosa J, Henderson DK, Freifeld A. Rapid identification of respiratory viruses: impact on isolation practices and transmission among immunocompromised pediatric patients. *Infect Control Hosp Epidemiol*. 1996;17: 581-6.
7. Barenfanger J, Drake C, Leon N, Mueller T, Trout T. Clinical and financial benefits of rapid detection of respiratory viruses: an outcome study. *J Clin Microbiol*. 2000;38:2824-8.
8. Public Health Ontario. The story of COVID-19 testing in Ontario. Published 2020. Available at: <https://www.publichealthontario.ca/en/about/blog/2020/story-COVID-19-testing-ontario>. Accessed March 17, 2021.
9. Government of Canada. COVID-19 daily epidemiology update. Available at: <https://health-infobase.canada.ca/covid-19/epidemiological-summary-covid-19-cases.html>. Accessed May 17, 2021.
10. Katikar M. COVID-19: Early detection and timely diagnosis in a neurological setup. *Indian J Anaesth*. 2020;64(9):805-7.
11. Government of Canada. Priority strategies to optimize testing and screening for COVID-19 in Canada: Report. January 2021. Available at: <https://www.canada.ca/en/health-canada/news/2021/01/priority-strategies-to-optimize-testing-and-screening-for-covid-19-in-canada-report-from-the-covid-19-testing-and-screening-expert-advisory-panel.html>. Accessed March 17, 2021.
12. Medtech Canada. Position Paper. Call for comprehensive COVID-19 testing strategies in Canada. 2021. Available at: https://cdn.yrnaws.com/medtechcanada.org/resource/resmgr/Medtech_Canada_Position_Pape.pdf. Accessed May 17, 2021.
13. World Health Organization. Transmission of SARS-CoV-2: implications for infection prevention precautions. Available at: <https://www.who.int/news-room/commentaries/detail/transmission-of-sars-cov-2-implications-for-infection-prevention-precautions>. Accessed March 19, 2021.
14. Tepper, J. The "forgotten" fourth aim of quality improvement in health care – improving the experience of providers. *CMAJ blogs*. Available at: <https://cmajblogs.com/the-forgotten-fourth-aim-of-quality-improvement-in-health-care-improving-the-experience-of-providers/>. Accessed March 17, 2021.